Name

NEOGAP Therapeutics

Legal name

Neogap Therapeutics AB

Website

https://neogap.se

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Personalised Cancer Immunotherapy

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)

akta.pro secondary industry

CAR-T & TCR-T Therapies (HLAAABAC)

Keywords

• Personalised cancer immunotherapy
• Cell-based immunotherapy
• Neoantigen targeting therapy
• T cell expansion technology
• Immuno-oncology therapeutics

Headquarters

HQ city

Stockholm

HQ country

Sweden

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Cell therapy product commercialization: Pre-revenue clinical-stage company developing personalised cancer immunotherapy. Revenue expected from eventual commercialisation of pTTL therapy following clinical development and regulatory approval, with potential out-licensing to pharmaceutical partners.
2. Technology licensing: EpiTCer technology platform applicable beyond cancer to autoimmune diseases, potentially licensable to pharmaceutical and biotech companies

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

NEOGAP Therapeutics develops personalised cancer cell-based immunotherapy (pTTL) using a patient's own T cells, supported by two proprietary platforms: PIOR®, a machine-learning software that identifies and ranks up to 36 tumour-specific neoantigens per patient, and EpiTCer®, a patented bead-based technology that expands and trains those T cells to target the identified neoantigens. The lead clinical programme targets advanced/metastatic colorectal cancer and is currently in a Phase I/II trial at Swedish hospitals.

Product overview

NEOGAP Therapeutics offers a unified personalised cancer immunotherapy platform consisting of three integrated components: pTTL (Personalised Tumour Trained Lymphocytes) as the core therapy product, PIOR® software for neoantigen identification and selection using machine learning, and EpiTCer® technology for T cell expansion and training. The platform uses the patient's own cells from tumour-draining lymph nodes to create a tailor-made treatment targeting patient-specific neoantigens, with initial focus on advanced colorectal cancer.

Differentiator

Problem solved

Functional benefit

Products and services

• pTTL (personalised Tumour Trained Lymphocytes) A personalised cell-based immunotherapy that enhances the patient's own T cells from tumour-draining lymph nodes to fight cancer by training them to target patient-specific tumour neoantigens. Initially focused on advanced/metastatic colorectal cancer, with potential application across solid tumour types. Currently in Phase I/II clinical trial.
• PIOR® (Personalised Immuno-Oncology Ranking) A proprietary machine-learning software platform that uses DNA and RNA next-generation sequencing data from tumour and healthy tissue to identify, select, and rank up to 36 tumour-specific neoantigens per patient. PIOR is a foundational component of the pTTL therapy workflow and is GDPR-compliant.
• EpiTCer® Technology A patented technology platform using superparamagnetic microbeads coupled with personalised neoantigens that are taken up by antigen-presenting cells, which then activate and expand tumour-targeting T cells. Used to expand and train patient T cells for the pTTL therapy, with additional applications in detecting antigen-specific autoreactive T cells in autoimmune disease research.

Quantifiable outcome

• Positive safety profile: no serious treatment-related adverse events observed in initial trial data
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Partnerships

Six partnerships are on record, tiered major, core and minor.

• Weill Cornell MedicinemajorStrategic or Co-development Partner · 5 November 2025Vinnova-funded (SEK 1M) collaboration to explore pathways for US clinical studies. Combines Neogap's clinical expertise with Weill Cornell's TIL therapy and translational immuno-oncology experience, preparing for potential Phase II US sites.
• NorthX BiologicscoreStrategic or Co-development Partner · 4 November 2024Strategic collaboration with leading CDMO to advance manufacturing strategies for personalised cancer cell therapy. Partnership aims to optimise and scale production for future clinical trials and commercialisation through GMP process industrialisation.
• OkomeraminorStrategic or Co-development Partner · 25 March 2024French biotech collaboration under Eurostars funding (SEK 5M) to develop analysis method for T cell activity against tumours. Okomera contributes organoid screening technology and killing assay methodology to predict therapy efficacy.
• CellerysminorStrategic or Co-development Partner · 4 May 2023Zurich-based company using Neogap's EpiTCer technology in Phase II study for multiple sclerosis therapy RED4MS. Neogap provides technology for detecting autoreactive T cells as biomarkers.
• Clinical Trial Consultants AB (CTC)minorImplementation/ SI/ Consulting PartnerSwedish CRO contracted for first clinical trial in colorectal cancer, providing clinical trial management services.
• CDMO NorthX BiologicscoreStrategic or Co-development PartnerManufacturing framework development to support later-stage clinical trials and future commercialisation as part of EIC grant collaboration.

Scale indicators6 records

Recent moves2 records

Expansion highlights6 records

Direct peers

• Achilles Therapeutics: London-based clinical-stage biotech developing personalized neoantigen TIL therapies (cNeT) using DNA sequencing to identify tumor-specific clonal neoantigens and expand tumor-infiltrating lymphocytes. Extremely close mechanistic analog to Neogap's pTTL approach (both use patient T cells + neoantigen targeting without genetic modification) and is in Phase I/II for NSCLC and melanoma.
• Iovance Biotherapeutics: US clinical and commercial-stage cell therapy company developing autologous TIL therapies for solid tumors. FDA-approved lifileucel (Amtagvi) for advanced melanoma and ongoing trials in cervical cancer and other indications. Most commercially advanced direct competitor in TIL therapy space.
• Adaptimmune Therapeutics: Clinical-stage cell therapy company developing engineered TCR-T cell therapies (SPEAR T-cells) targeting solid tumor antigens including neoantigens. FDA-approved Tecelra for synovial sarcoma. Comparable in mechanism (T cell receptor-mediated targeting of tumor antigens) and clinical-stage T cell therapy execution.
• Immatics: German clinical-stage biotech developing TCR-based immunotherapies (ACTengine, ACTallo) and bispecifics (TCER) targeting tumor-specific peptides including neoantigens. Very close peer on the neoantigen identification and TCR-T cell therapy axis, with multiple clinical programs and Big Pharma partnerships.
• Instil Bio: US clinical-stage cell therapy company developing autologous TIL therapies (ITIL-306 and others) for solid tumors including melanoma, cervical, and lung cancers. Direct TIL therapy peer with comparable clinical-stage positioning and manufacturing approach.
• Turnstone Biologics: Clinical-stage biotech developing next-generation tumor-infiltrating lymphocyte (TIL) therapies with selected TIL (Selected TIL) and viral immunotherapy platforms for solid tumors. Direct mechanistic peer to Neogap's pTTL in TIL therapy space.
• Marker Therapeutics: US clinical-stage cell therapy company developing multi-tumor-associated antigen (MultiTAA)-specific T cell therapies for solid tumors and hematologic malignancies. Smaller emerging peer using non-engineered, antigen-specific T cell approaches for solid tumors.

Broad incumbents

• Bristol-Myers Squibb: Global pharmaceutical leader with approved CAR-T cell therapies (Breyanzi, Abecma) and a broad immuno-oncology portfolio including checkpoint inhibitors. Key potential out-licensing partner and broad competitive incumbent in cell therapy and oncology.
• BioNTech: German biotech with multiple personalized neoantigen programs including FixVac (off-the-shelf mRNA cancer vaccines), individualized mRNA vaccines (BNT122 in Phase II with Genentech), and CAR-T programs (BNT211). Broad incumbent in personalized cancer immunotherapy and likely strategic partner/acquirer for Neogap.
• Moderna: US biotech with mRNA-4157 individualized neoantigen cancer vaccine in Phase III (KEYNOTE-942 partnership with Merck). Adjacent platform competing for the same personalized neoantigen immunotherapy value pool as Neogap's PIOR + EpiTCer platform, though via a different modality (mRNA vaccine vs. cell therapy).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/neogap-ab

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries1 record

Funding overview

Funding rounds6 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NEOGAP Therapeutics